A small protein involved in neurodegeneration leading to Parkinson’s disease also drives a type of skin cancer known as melanoma, new research finds.

The study, published in the journal Science Advances, suggests new avenues for drug development to reduce the risk of developing both Parkinson’s and skin cancer by targeting the alpha-synuclein protein, which appears to have a critical role in regulating cellular functions.

“Developing drugs that target alpha-synuclein may be useful in both diseases,” said the senior author.